Sevilla

• A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended recruitment
  2024-519561-22-00 4 2025-07-07 Obesity
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended recruitment
  2024-519417-57-00 5 2025-06-25 Thyroid eye disease
• A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended recruitment
  2024-515973-82-00 4 2025-06-23 ACPA-Positive Rheumatoid Arthritis
• A clinical study of sotatercept in people with pulmonary arterial hypertension Ended recruitment
  2024-518687-12-00 4 2025-06-19 Pulmonary Arterial Hypertension (PAH)
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended recruitment
  2024-514163-26-00 4 2025-06-09 Advanced Melanoma
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study) … Ended recruitment
  2024-513511-27-00 4 2025-05-29 HR-negative/HER2-negative resectable stage I TNBC.
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended recruitment
  2024-515773-99-00 4 2025-05-26 Pulmonary Hypertension
• A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef … Ended recruitment
  2024-515907-20-00 9 2025-05-23 Primary biliary cholangitis (PBC)
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516814-39-00 5 2025-05-20 Chronic rhinosinusitis with nasal polyps
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• Phase 2 Study of CVN424 Ended recruitment
  2024-516811-25-00 4 2025-05-15 Parkinson Disease
• A study to investigate the effect and safety of BW-20805 in adult participants with hereditary angioedema Ended recruitment
  2024-518207-22-00 4 2025-05-15 Hereditary Angioedema
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI … Ended recruitment
  2023-505601-16-00 5 2025-04-22 Chronic Migraine
• A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended recruitment
  2024-517741-14-00 9 2025-04-22 advanced non-squamous non-small cell lung cancer (NSCLC)
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A Study of Remternetug in Early Alzheimer’s Disease Ended recruitment
  2024-515656-20-00 5 2025-04-15 Alzheimer’s Disease
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease

Showing 769–792 of 1,630 trials